Ocugen (NASDAQ:OCGN) Issues Earnings Results, Misses Expectations By $0.01 EPS

Key Points

• Ocugen reported ($0.06) EPS, missing consensus by $0.01, and the stock fell about 19.7% to $1.49 on the news.
• The company announced a $115 million convertible note offering (expected to close May 7) that would lift cash to ~$112.1M (or $127.1M with warrants) and reportedly extend its cash runway into 2028, but pre‑financing cash was only $32.2M and Q1 operating expenses were $19.4M, signaling potential dilution or further funding risk.
• Clinical programs advanced: Phase II OCU410 showed a 31% reduction in lesion growth at 12 months vs control, and OCU400 completed enrollment in the 140‑patient LIMELIGHT Phase III with plans for a rolling BLA in Q3 2026, top‑line in Q1 2027 and potential approval targeted for Q4 2027.

Ocugen (NASDAQ:OCGN - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.06) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.01), Zacks reports. Ocugen had a negative return on equity of 2,626.38% and a negative net margin of 1,192.18%.

Here are the key takeaways from Ocugen's conference call:

• Ocugen announced a $115 million convertible senior notes offering expected to close May 7, which management says would bring expected cash equivalents and restricted cash to $112.1 million (or $127.1 million if remaining warrants are exercised) and extend cash runway into 2028.
• Phase II data for OCU410 (GA) showed the medium dose produced a 31% reduction in lesion growth at 12 months versus control (p<0.05), ~2x the treatment effect of approved intravitreal therapies, with a favorable tolerability profile after a single one‑time subretinal injection.
• OCU400 (RP) completed enrollment in the 140‑patient LIMELIGHT Phase III trial, plans to begin a rolling BLA in Q3 2026, expects Phase III top‑line in Q1 2027 and potential approval targeted for Q4 2027, and cites durable 3‑year benefit and no drug‑related SAEs in earlier cohorts.
• OCU410ST (Stargardt) dosing in the pivotal GARDian3 trial finished ahead of schedule (63 patients); an interim outcome analysis is planned for Q3 2026 with top‑line data expected in Q2 2027 and a potential BLA mid‑2027, but the adaptive DMC review could require sample‑size adjustments and timing changes.
• Financials show rising spend and ongoing losses — Q1 operating expenses rose to $19.4 million with a $0.06 net loss per share and cash of $32.2 million as of March 31, 2026 (pre‑financing), meaning execution depends on the planned financing and future regulatory outcomes and may involve dilution or additional funding needs.

Ocugen Stock Down 19.7%

OCGN traded down $0.37 during trading on Tuesday, reaching $1.49. The stock had a trading volume of 17,094,724 shares, compared to its average volume of 7,519,063. The stock's 50 day moving average is $1.88 and its two-hundred day moving average is $1.59. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 8.04. The company has a market capitalization of $502.70 million, a price-to-earnings ratio of -6.46 and a beta of 2.30. Ocugen has a one year low of $0.64 and a one year high of $2.73.

Analyst Ratings Changes

OCGN has been the subject of a number of research analyst reports. Canaccord Genuity Group initiated coverage on Ocugen in a research note on Tuesday, March 17th. They issued a "buy" rating and a $12.00 price target for the company. Oppenheimer initiated coverage on Ocugen in a research note on Wednesday, March 11th. They issued an "outperform" rating and a $10.00 price target for the company. Chardan Capital reaffirmed a "buy" rating and issued a $7.00 price target on shares of Ocugen in a research note on Wednesday, March 25th. HC Wainwright raised their price target on Ocugen from $7.00 to $10.00 and gave the stock a "buy" rating in a research note on Wednesday, March 25th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Ocugen in a research note on Thursday, January 22nd. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $9.75.

Hedge Funds Weigh In On Ocugen

A number of institutional investors have recently added to or reduced their stakes in OCGN. SmartHarvest Portfolios LLC bought a new position in Ocugen in the fourth quarter worth $31,000. NewEdge Advisors LLC raised its holdings in Ocugen by 198.0% in the second quarter. NewEdge Advisors LLC now owns 36,814 shares of the company's stock worth $36,000 after purchasing an additional 24,460 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Ocugen by 56.7% during the second quarter. BNP Paribas Financial Markets now owns 36,822 shares of the company's stock valued at $36,000 after acquiring an additional 13,326 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new position in shares of Ocugen during the fourth quarter valued at $38,000. Finally, Caitong International Asset Management Co. Ltd increased its holdings in shares of Ocugen by 28,222.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 30,305 shares of the company's stock valued at $41,000 after acquiring an additional 30,198 shares in the last quarter. Institutional investors own 10.27% of the company's stock.

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.